Proper news from Britain - News from Britain you won’t find anywhere else. Not the tosh the big media force-feed you every day!
An AstraZeneca cancer drug received the green light by European regulators yesterday.
The London-listed drugs maker revealed that its bladder cancer treatment Imfinzi has been approved to treat adult patients in the European Union.
It comes amid reports that AstraZeneca – the FTSE 100's largest company – is considering moving its listing from the UK to the US in what would be a hammer blow to London's stock market.
The speculation was fuelled by the pharmaceutical sector's growing frustration with the UK's rules on approving medicines as well as a row over drug prices between the industry and the NHS.

Dave Fredrickson, head of AstraZeneca's oncology haematology unit, said: 'Imfinzi is poised to transform the standard of care for muscle-invasive bladder cancer in Europe.'
AstraZeneca shares edged up 1.3 per cent yesterday.
DIY INVESTING PLATFORMS
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
Compare the best investing account for you